Evidence map›Paper›PMID 35741800›Full record

ArticleGenes2022

Correlation between Genomic Variants and Worldwide Epidemiology of Prostate Cancer.

Giovana Miranda Vieira, Laura Patrícia Albarello Gellen, Diana Feio da Veiga Borges Leal, Lucas Favacho Pastana, Lui Wallacy Morikawa Souza Vinagre, Vitória Teixeira Aquino, Marianne Rodrigues Fernandes, Paulo Pimentel de Assumpção, Rommel Mario Rodríguez Burbano, Sidney Emanuel Batista Dos Santos and 1 more

Abstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giovana Miranda VieiraResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.
Laura Patrícia Albarello GellenResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.ORCID 0000-0001-8620-5987
Diana Feio da Veiga Borges LealResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.ORCID 0000-0003-3125-6052
Lucas Favacho PastanaResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.
Lui Wallacy Morikawa Souza VinagreResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.ORCID 0000-0002-7063-6149
Vitória Teixeira AquinoResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.
Marianne Rodrigues FernandesResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.ORCID 0000-0002-1396-3442
Paulo Pimentel de AssumpçãoResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.
Rommel Mario Rodríguez BurbanoResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.ORCID 0000-0002-4872-234X
Sidney Emanuel Batista Dos SantosResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.
Ney Pereira Carneiro Dos SantosResearch Center of Oncology, Federal University of Pará Belém, Belém 66073-000, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) incidence and mortality vary across territories and populations. This can be explained by the genetic factor of this disease. This article aims to correlate the epidemiological data, worldwide incidence, and mortality of PCa with single-nucleotide polymorphisms (SNPs) associated with the susceptibility and severity of this neoplasm in different populations. Eighty-four genetic variants associated with prostate cancer susceptibility were selected from the literature through genome association studies (GWAS). Allele frequencies were obtained from the 1000 Genomes Project, and epidemiological data were obtained from Surveillance, Epidemiology, and End Results (SEER). The PCa incidence, mortality rates, and allele frequencies of variants were evaluated by Pearson's correlation. Our study demonstrated that 12 SNPs (rs2961144, rs1048169, rs7000448, rs4430796, rs2066827, rs12500426, rs6983267, rs11649743, rs2075110, rs114798100, rs855723, and rs2075109) were correlated with epidemiological data in different ethnic groups. Ten SNPs (rs2961144, rs1048169, rs7000448, rs4430796, rs2066827, rs12500426, rs11649743, rs2075110, rs114798100, and rs2075109) were positively correlated with the mortality rate. Seven SNPs (rs1048169, rs2961144, rs7000448, rs4430796, rs2066827, rs12500426, and rs114798100) were positively correlated with incidence. Positive correlations of incidence and mortality rates were more frequent in the African population. The genetic variants investigated here are likely to predispose to PCa and could play a role in its progression and aggressiveness. This genetic study demonstrated here is promising for implementing personalized strategies to screen for prostate cancer in diverse populations.

Indexed as

Genetic Predisposition to DiseaseProstatic NeoplasmsGene FrequencyGenomicsHumansMalePolymorphism, Single Nucleotideepidemiologygenetic risk variantpopulationprostate cancerseveritysusceptibility

Identifiers

PMID35741800
PMCPMC9222668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.